Update Breast Cancer 2019 Part 2-Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice

Janni W, Schneeweiss A, Mueller V, Woeckel A, Lux MP, Hartkopf AD, Nabieva N, Taran FA, Tesch H, Overkamp F, Lueftner D, Belleville E, Schuetz F, Fasching P, Fehm TN, Kolberg HC, Ettl J (2019)

Publication Type: Journal article, Review article

Publication year: 2019

Journal

Geburtshilfe und Frauenheilkunde Georg Thieme Verlag

Book Volume: 79

Pages Range: 268-280

Journal Issue: 3

DOI: 10.1055/a-0842-6661

Abstract

The treatment of patients with advanced breast cancer has developed further in recent years. In addition to therapeutic progress in the established subgroups (hormone receptor and HER2 status), there are now therapies which are geared to individual molecular characteristics, such as PARP inhibitor therapy in BRCA-mutated patients. In addition to this, tests are being developed which are intended to establish addition-al markers within subgroups in order to predict the efficacy of a therapy. PI3K mutation testing in HER2-negative, hormonereceptor- positive tumours and PD-L1 testing of immune cells in triple-negative tumours are expected to become established in clinical practice in order to select patients for the respective therapies. With new therapeutic approaches, new adverse effects also appear. The management of these adverse effects, just as those of classical therapy (supportive therapy), is essential with the introduction of new treatments in order to preserve patients ' quality of life. Knowledge regarding measures to preserve and improve quality of life has significantly increased in recent years. Lifestyle factors should be taken into account, as should modern therapeutic methods. This review summarises the latest studies and publications and evaluates them in regard to the relevance for clinical practice.

Authors with CRIS profile

Naiba Nabieva Department of Obstetrics and Gynaecology Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Universitätsklinikum Ulm DE Germany (DE) Universitätsklinikum Heidelberg DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Universitätsklinikum Würzburg DE Germany (DE) Eberhard Karls Universität Tübingen DE Germany (DE) Centrum für Hämatologie und Onkologie Bethanien DE Germany (DE) OncoConsult DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) ClinSol GmbH & Co.KG DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Marienhospital Bottrop DE Germany (DE) Technische Universität München (TUM) DE Germany (DE) Universitätsklinikum Düsseldorf DE Germany (DE)

How to cite

APA:

Janni, W., Schneeweiss, A., Mueller, V., Woeckel, A., Lux, M.P., Hartkopf, A.D.,... Ettl, J. (2019). Update Breast Cancer 2019 Part 2-Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe und Frauenheilkunde, 79(3), 268-280. https://dx.doi.org/10.1055/a-0842-6661

MLA:

Janni, Wolfgang, et al. "Update Breast Cancer 2019 Part 2-Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice." Geburtshilfe und Frauenheilkunde 79.3 (2019): 268-280.

BibTeX: Download